01 — At a Glance
The Diabetes Company That Forgot It Sold Other Drugs
- 52-Week High / Low₹6,718 / ₹3,495
- FY25 Revenue (Full Year)₹1,837 Cr
- FY25 PAT (Full Year)₹327 Cr
- Full-Year EPS (FY25)₹142
- Q4 EPS₹26.83
- Book Value₹326
- Price to Book10.8x
- Dividend Yield3.34%
- Debt / Equity0.02x
- 5-Year Revenue CAGR-8.74%
The Auditor’s Sigh: Sanofi India closed FY25 with ₹1,837 crore revenue (down 9% YoY), ₹327 crore PAT (up 1%, thanks to OPEX cuts), 57.5% ROCE, and a stock price that fell 37% in one year. Domestic sales are flat. Exports are down 54% in Q4. They’re paying out 87% dividend on a declining earnings base. Management is calling this “transformation.” The market is calling it a liquidation. Both are probably right.
02 — Introduction
When a Pharma Giant Decides to Become a Startup
Welcome to Sanofi India Limited, a pharmaceutical company that once looked like a balanced portfolio, then decided to be the insulin guy. Not just good at insulin. THE insulin guy. So aggressively committed to insulin that they literally divested their entire consumer healthcare business in Jun 2024 to avoid the distraction. Imagine owning a Ferrari, a truck, and a bicycle, then selling the truck and bicycle because you were really, really into Ferraris.
The company has been in India since 1956 — that’s 69 years of continuity — and manages to be top 20 in the Indian Pharmaceutical Market despite shrinking revenue. Controlled by Hoechst GmbH (60.4%), a Sanofi Global subsidiary. Follows calendar year reporting, which makes peer comparison friction but makes French HQ conversations easy. Five billion+ tablet capacity at their Goa manufacturing facility. One flagship brand — Lantus — that dominates the basal insulin market with 50% share and a position in the Top 5 IPM brands for over a decade.
But growth? Growth is in the rear-view mirror. FY25 was a -9% revenue year, with exports down 54% in Q4. Management’s response: strategic pivot to insulin leadership + partnership distribution model for legacy brands. The company demerged consumer healthcare (Allegra, Nimesulide portfolio) to a standalone listed entity to focus. New MD (Deepak Arora) appointed Oct 2025. Concall on Feb 26, 2026 claims “transformed business model” for “sustainable, profitable growth.” Translation: we’re smaller, leaner, and we’ve stopped pretending we’re a diversified pharma company.
The question is: is this transformation real, or is it just rebranding the ship as it sinks?
Concall Note (Feb 2026): “Pivotal transformation to position ourselves for sustainable, profitable growth.” Also: “Domestic sales flat for 2025.” — If domestic is flat and the company is “transformed,” something does not add up. Growth is *supposed* to be the other side of that coin.
03 — Business Model: The One-Trick Pony Gets Pony.
Insulin, Partnerships, and the Art of Abandonment
Sanofi India’s portfolio now breaks down neatly: Diabetes (including Lantus + Toujeo + Soliqua), Cardiovascular (via Emcure partnership), CNS (via Cipla partnership), and OAD (oral anti-diabetes). That’s it. The neutraceuticals got divested. Consumer healthcare got spun off. Auto-care products exited the building. What remains is essentially a specialty pharma play in insulin, cardiovascular, and niche CNS with zero manufacturing in India for most of it — they outsource to 12 CMOs nationwide and rely heavily on Goa facility (61% output for exports).
Revenue mix: 93% products, 6% services, 1% other. But the real action is in what comes next. Lantus is mature at 50% market share. Toujeo (next-gen basal insulin) grew 20% in CY23 and is accelerating in Q4 FY25 (“registered DD growth” per concall). Soliqua (premixed insulin) got CARE account access and is “maximizing GLP-1 market growth” (their words). New molecules in pipeline: Teplizumab (Type 1 diabetes, stage 3 in US), Brivekimab (Type 1, stage 3), Frexalimab (Type 1). Real clinical pipelines, not fake fluff.
The partnership model is critical: Emcure handles cardiovascular distribution (5-year exclusive), Cipla handles CNS (5-year exclusive). This outsources go-to-market risk, cuts fixed OPEX, and (management hopes) lets them focus on what they’re good at: insulin science and digital-first customer engagement.
Lantus50%Basal Insulin Share
Toujeo12%Basal Segment
Export Volume61%From Goa Facility
Portfolio MixDiabetes 51%% of sales
Manufacturing Note: Goa facility produces Paracetamol-Codeine (100% export), Ramipril, Fexofenadine, Glimepiride, Depakine (Sodium Valproate). No direct diabetes drugs manufactured in India — Lantus/Toujeo are imported and repackaged. That’s the Achilles heel: every rupee of depreciation is another blade into margins.
💬 Think the partnership model (outsourcing CV & CNS distribution) is genius risk transfer or code for “we gave up on those markets”? Drop your take in the comments.
04 — Financials Overview
Q4 FY25: The Numbers That Tell the Real Story
